Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact
Center for Computational Systems Medicine
leaf

Gene summary

leaf

Malignant transformation analysis

leaf

Malignant transformation related pathway analysis

leaf

Cell-cell communication analysis

leaf

Single-cell gene regulatory network inference analysis

leaf

Somatic mutation of malignant transformation related genes

leaf

Related drugs of malignant transformation related genes

Gene: ETF1

Gene summary for ETF1

check button Gene summary.

Gene informationSpeciesHuman
Gene symbol

ETF1

Gene ID

2107

Gene nameeukaryotic translation termination factor 1
Gene AliasD5S1995
Cytomap5q31.2
Gene Typeprotein-coding
GO ID

GO:0000184

UniProtAcc

P62495


Top

Malignant transformation analysis

check button Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells
check button Malignant transformation involving gene list.
Entrez IDSymbolReplicatesSpeciesOrganTissueAdj P-valueLog2FCMalignancy
2107ETF1LZE4THumanEsophagusESCC3.29e-138.92e-020.0811
2107ETF1LZE5THumanEsophagusESCC3.56e-03-1.05e-010.0514
2107ETF1LZE7THumanEsophagusESCC1.61e-021.04e-010.0667
2107ETF1LZE8THumanEsophagusESCC5.77e-121.91e-010.067
2107ETF1LZE20THumanEsophagusESCC7.59e-03-2.78e-010.0662
2107ETF1LZE22D1HumanEsophagusHGIN4.89e-04-3.29e-010.0595
2107ETF1LZE22THumanEsophagusESCC8.65e-04-5.82e-020.068
2107ETF1LZE24THumanEsophagusESCC3.92e-053.76e-010.0596
2107ETF1LZE6THumanEsophagusESCC3.01e-051.21e-010.0845
2107ETF1P1T-EHumanEsophagusESCC9.52e-034.98e-020.0875
2107ETF1P2T-EHumanEsophagusESCC7.01e-225.57e-010.1177
2107ETF1P4T-EHumanEsophagusESCC4.92e-163.03e-010.1323
2107ETF1P5T-EHumanEsophagusESCC8.12e-162.43e-010.1327
2107ETF1P8T-EHumanEsophagusESCC6.02e-21-6.31e-020.0889
2107ETF1P9T-EHumanEsophagusESCC1.03e-115.90e-020.1131
2107ETF1P10T-EHumanEsophagusESCC1.20e-162.57e-020.116
2107ETF1P11T-EHumanEsophagusESCC4.57e-067.56e-010.1426
2107ETF1P12T-EHumanEsophagusESCC1.13e-198.18e-010.1122
2107ETF1P15T-EHumanEsophagusESCC1.96e-246.24e-010.1149
2107ETF1P16T-EHumanEsophagusESCC1.33e-221.79e-010.1153
Page: 1 2 3 4 5 6 7 8 

check button Transcriptomic changes along malignancy continuum.
TissueExpression DynamicsAbbreviation
EsophagusThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ESCC: Esophageal squamous cell carcinoma
HGIN: High-grade intraepithelial neoplasias
LGIN: Low-grade intraepithelial neoplasias
LiverThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.HCC: Hepatocellular carcinoma
NAFLD: Non-alcoholic fatty liver disease
Oral CavityThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.EOLP: Erosive Oral lichen planus
LP: leukoplakia
NEOLP: Non-erosive oral lichen planus
OSCC: Oral squamous cell carcinoma
ProstateThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.BPH: Benign Prostatic Hyperplasia
SkinThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.AK: Actinic keratosis
cSCC: Cutaneous squamous cell carcinoma
SCCIS:squamous cell carcinoma in situ
ThyroidThe image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.ATC: Anaplastic thyroid cancer
HT: Hashimoto's thyroiditis
PTC: Papillary thyroid cancer
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

check buttonFind out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer
check button Figure of enriched GO biological processes.
TissueDisease StageEnriched GO biological Processes
ColorectumADGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumSERGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSSGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumMSI-HGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
ColorectumFAPGO analysis - Figure of enriched GO biological processes: Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).
Page: 1 2 3 4 5 6 7 8 9 

check button Enriched GO biological processes.
GO IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustCount
GO:003465511LiverCirrhoticnucleobase-containing compound catabolic process171/4634407/187239.07e-159.33e-13171
GO:00224117LiverCirrhoticcellular component disassembly182/4634443/187231.59e-141.54e-12182
GO:000640111LiverCirrhoticRNA catabolic process126/4634278/187234.64e-144.10e-12126
GO:000640211LiverCirrhoticmRNA catabolic process109/4634232/187231.30e-131.09e-11109
GO:000095611LiverCirrhoticnuclear-transcribed mRNA catabolic process58/4634112/187236.55e-103.06e-0858
GO:00329846LiverCirrhoticprotein-containing complex disassembly82/4634224/187234.78e-055.54e-0482
GO:00001843LiverCirrhoticnuclear-transcribed mRNA catabolic process, nonsense-mediated decay20/463437/187231.25e-041.23e-0320
GO:00064791LiverCirrhoticprotein methylation61/4634181/187234.13e-032.21e-0261
GO:00082131LiverCirrhoticprotein alkylation61/4634181/187234.13e-032.21e-0261
GO:000218122LiverHCCcytoplasmic translation132/7958148/187239.09e-335.76e-30132
GO:004427021LiverHCCcellular nitrogen compound catabolic process303/7958451/187239.76e-273.64e-24303
GO:004670021LiverHCCheterocycle catabolic process299/7958445/187232.07e-267.29e-24299
GO:190136121LiverHCCorganic cyclic compound catabolic process325/7958495/187236.52e-262.18e-23325
GO:001943921LiverHCCaromatic compound catabolic process309/7958467/187231.56e-254.94e-23309
GO:000640121LiverHCCRNA catabolic process201/7958278/187233.88e-241.02e-21201
GO:003465521LiverHCCnucleobase-containing compound catabolic process273/7958407/187234.84e-241.23e-21273
GO:000640221LiverHCCmRNA catabolic process169/7958232/187234.50e-216.96e-19169
GO:002241112LiverHCCcellular component disassembly282/7958443/187231.02e-191.38e-17282
GO:000641722LiverHCCregulation of translation287/7958468/187238.79e-178.08e-15287
GO:000095621LiverHCCnuclear-transcribed mRNA catabolic process84/7958112/187232.54e-121.18e-1084
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 

check button Enriched KEGG pathways.
Pathway IDTissueDisease StageDescriptionGene RatioBg Ratiopvaluep.adjustqvalueCount
hsa030159EsophagusHGINmRNA surveillance pathway30/138397/84652.48e-042.69e-032.14e-0330
hsa0301514EsophagusHGINmRNA surveillance pathway30/138397/84652.48e-042.69e-032.14e-0330
hsa0301524EsophagusESCCmRNA surveillance pathway72/420597/84656.12e-074.10e-062.10e-0672
hsa0301534EsophagusESCCmRNA surveillance pathway72/420597/84656.12e-074.10e-062.10e-0672
hsa030154LiverCirrhoticmRNA surveillance pathway46/253097/84651.92e-041.30e-038.03e-0446
hsa0301511LiverCirrhoticmRNA surveillance pathway46/253097/84651.92e-041.30e-038.03e-0446
hsa0301521LiverHCCmRNA surveillance pathway66/402097/84653.16e-051.88e-041.04e-0466
hsa0301531LiverHCCmRNA surveillance pathway66/402097/84653.16e-051.88e-041.04e-0466
hsa030158Oral cavityOSCCmRNA surveillance pathway75/370497/84651.30e-112.01e-101.02e-1075
hsa0301513Oral cavityOSCCmRNA surveillance pathway75/370497/84651.30e-112.01e-101.02e-1075
hsa0301523Oral cavityLPmRNA surveillance pathway50/241897/84651.39e-061.50e-059.66e-0650
hsa0301533Oral cavityLPmRNA surveillance pathway50/241897/84651.39e-061.50e-059.66e-0650
hsa0301541Oral cavityEOLPmRNA surveillance pathway30/121897/84652.26e-051.20e-047.07e-0530
hsa0301551Oral cavityEOLPmRNA surveillance pathway30/121897/84652.26e-051.20e-047.07e-0530
hsa030156Oral cavityNEOLPmRNA surveillance pathway25/111297/84655.70e-043.18e-032.00e-0325
hsa030157Oral cavityNEOLPmRNA surveillance pathway25/111297/84655.70e-043.18e-032.00e-0325
hsa030155ProstateBPHmRNA surveillance pathway32/171897/84652.20e-038.63e-035.34e-0332
hsa0301512ProstateBPHmRNA surveillance pathway32/171897/84652.20e-038.63e-035.34e-0332
hsa0301522ProstateTumormRNA surveillance pathway33/179197/84652.18e-038.60e-035.33e-0333
hsa0301532ProstateTumormRNA surveillance pathway33/179197/84652.18e-038.60e-035.33e-0333
Page: 1 

Top

Cell-cell communication analysis

check buttonIdentification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states
LigandReceptorLRpairPathwayTissueDisease Stage
Page: 1 

Top

Single-cell gene regulatory network inference analysis

check buttonFind out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states
TFCell TypeTissueDisease StageTarget GeneRSSRegulon Activity
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.
Page: 1 

Top

Somatic mutation of malignant transformation related genes

check buttonAnnotation of somatic variants for genes involved in malignant transformation
Hugo SymbolVariant ClassVariant ClassificationdbSNP RSHGVScHGVSpHGVSp ShortSWISSPROTBIOTYPESIFTPolyPhenTumor Sample BarcodeTissueHistologySexAgeStageTherapy TypesDrugsOutcome
ETF1SNVMissense_Mutationc.118N>Tp.Pro40Serp.P40SP62495protein_codingtolerated(0.06)possibly_damaging(0.845)TCGA-AC-A23H-01Breastbreast invasive carcinomaFemale>=65I/IIUnknownUnknownPD
ETF1SNVMissense_Mutationc.1081G>Cp.Glu361Glnp.E361QP62495protein_codingtolerated(0.1)benign(0.269)TCGA-AN-A0XW-01Breastbreast invasive carcinomaFemale<65III/IVUnknownUnknownSD
ETF1SNVMissense_Mutationnovelc.444N>Ap.Phe148Leup.F148LP62495protein_codingdeleterious(0.02)probably_damaging(0.989)TCGA-E2-A14O-01Breastbreast invasive carcinomaFemale>=65III/IVHormone TherapyarimidexSD
ETF1insertionNonsense_Mutationnovelc.495_496insGCCCGGCCCTGTCTCTACTAAAAATACAAAAATGTGACGGGCGCCp.Thr165_Arg166insAlaArgProCysLeuTyrTerLysTyrLysAsnValThrGlyAlap.T165_R166insARPCLY*KYKNVTGAP62495protein_codingTCGA-AR-A0TY-01Breastbreast invasive carcinomaFemale<65I/IIUnspecificPaclitaxelPD
ETF1SNVMissense_Mutationc.997C>Tp.Leu333Phep.L333FP62495protein_codingtolerated(0.08)benign(0.045)TCGA-C5-A2LX-01Cervixcervical & endocervical cancerFemale<65I/IIChemotherapycisplatinSD
ETF1SNVMissense_Mutationc.812N>Gp.Ser271Cysp.S271CP62495protein_codingtolerated(0.06)benign(0.366)TCGA-EK-A2PM-01Cervixcervical & endocervical cancerFemale>=65I/IIUnknownUnknownSD
ETF1SNVMissense_Mutationc.1051N>Ap.Glu351Lysp.E351KP62495protein_codingtolerated(0.06)benign(0.084)TCGA-JW-A5VJ-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownPD
ETF1SNVMissense_Mutationnovelc.1168G>Cp.Glu390Glnp.E390QP62495protein_codingtolerated(0.07)benign(0.123)TCGA-VS-A953-01Cervixcervical & endocervical cancerFemale<65I/IIUnknownUnknownPD
ETF1SNVMissense_Mutationc.913N>Ap.Val305Ilep.V305IP62495protein_codingtolerated(0.44)benign(0.007)TCGA-A6-5665-01Colorectumcolon adenocarcinomaFemale>=65I/IIUnknownUnknownPD
ETF1SNVMissense_Mutationc.365N>Tp.Thr122Metp.T122MP62495protein_codingdeleterious(0)possibly_damaging(0.904)TCGA-AA-3510-01Colorectumcolon adenocarcinomaMale>=65I/IIUnknownUnknownSD
Page: 1 2 3 4 5 6 

Top

Related drugs of malignant transformation related genes

check buttonIdentification of chemicals and drugs interact with genes involved in malignant transfromation
(DGIdb 4.0)
Entrez IDSymbolCategoryInteraction TypesDrug Claim NameDrug NamePMIDs
Page: 1